B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Guo, Jhe-Cyuan; Hsu, Ching‐Yun; Huang, Yen‐Lin; Lin, Chia‐Chi; Huang, Tzu‐Ting; Wu, I-Chen; Lin, Chen‐Yuan; Lien, Ming‐Yu; Kuo, Hung-Yang; Cheng, Ann‐Lii; Hsu, Chih‐Hung

doi:10.3389/fonc.2022.879398

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S3B). This trend aligns with a prior study reporting a positive correlation between B cell infiltration and clinical benefit to PD-1 targeted immunotherapy in advanced ESCC 26 and different cancer types. 27 …”

Section: Exploratory Analysissupporting

confidence: 91%

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Lee,

Park,

Kim

et al. 2024

OncoImmunology

View full text Add to dashboard Cite

Section: Exploratory Analysissupporting

confidence: 91%

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Lee,

Park,

Kim

et al. 2024

OncoImmunology

View full text Add to dashboard Cite

“…Lu et al reported that the PD-1/PD-L pathway also contributes to T cell and B cell development and activation [38]. Guo et al found that B cells in the TME were associated with clinical benefits in patients with advanced ESCC receiving anti-PD-1/PD-L1-based therapy [39]. However, a series of clinical trials have shown that the effective rate of immunotherapy is only about 12% to 30% in EC patients [40][41][42][43].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma

Jiang

Miao

Wang

et al. 2023

Aging

View full text Add to dashboard Cite

Our study aimed to observe the correlation between epidermal growth factor receptor (EGFR) and programmed cell death-ligand 1 (PD-L1) expression and evaluate prognostic potential of their co-expression in esophageal squamous cell carcinoma (ESCC) patients. EGFR and PD-L1 expression were evaluated by immunohistochemical analysis. We revealed that there was a positive correlation between EGFR and PD-L1 expression in ESCC (P = 0.004). According to the positive relationship between EGFR and PD-L1, all patients were divided into four groups: EGFR (+)/PD-L1 (+), EGFR (+)/PD-L1 (−), EGFR (−)/PD-L1 (+), and EGFR (−)/PD-L1 (−). In 57 ESCC patients without surgery, we found that EGFR and PD-L1 co-expression were statistically correlated with a lower objective response rate (ORR) (p = 0.029), overall survival (OS) (p = 0.018) and progression-free survival (PFS) (p = 0.045) than those with one or none positive protein. Furthermore, PD-L1 expression has a significant positive correlation with infiltration level of 19 immune cells, EGFR expression was significantly correlated with infiltration level of 12 immune cells. The infiltration level of CD8 T cell and B cell were negatively correlated with EGFR expression. On the contrary with EGFR, the infiltration level of CD8 T cell, and B cell were positively correlated with PD-L1 expression. In conclusion, EGFR and PD-L1 co-expression could predict poor ORR and survival in ESCC without surgery, indicating a subset of patients who may benefit from a combination of targeted therapy against EGFR and PD-L1, which may expand the population benefiting from immunotherapy and reduce the occurrence of hyper progressive diseases.

show abstract

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment

Shi,

Cheng,

Jiang

et al. 2024

Advanced Science

View full text Add to dashboard Cite

B cells are crucial component of humoral immunity, and their role in the tumor immune microenvironment (TME) has garnered significant attention in recent years. These cells hold great potential and application prospects in the field of tumor immunotherapy. Research has demonstrated that the TME can remodel various B cell functions, including proliferation, differentiation, antigen presentation, and antibody production, thereby invalidating the anti‐tumor effects of B cells. Concurrently, numerous immune checkpoints (ICs) on the surface of B cells are upregulated. Aberrant B‐cell IC signals not only impair the function of B cells themselves, but also modulate the tumor‐killing effects of other immune cells, ultimately fostering an immunosuppressive TME and facilitating tumor immune escape. Blocking ICs on B cells is beneficial for reversing the immunosuppressive TME and restoring anti‐tumor immune responses. In this paper, the intricate connection between B‐cell ICs and the TME is delved into, emphasizing the critical role of targeting B‐cell ICs in anti‐tumor immunity, which may provide valuable insights for the future development of tumor immunotherapy based on B cells.

show abstract

B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Cited by 5 publications

References 31 publications

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment

Contact Info

Product

Resources

About